Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
9.32
+0.24 (2.60%)
Nov 21, 2024, 1:28 PM EST - Market open
Enanta Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | Sep '19 Sep 30, 2019 | 2018 - 2014 |
| Operating Revenue | 71.96 | 79.2 | 86.16 | 97.07 | 122.47 | 205.2 | Upgrade
|
| Revenue | 71.96 | 79.2 | 86.16 | 97.07 | 122.47 | 205.2 | Upgrade
|
| Revenue Growth (YoY) | -10.71% | -8.07% | -11.24% | -20.74% | -40.31% | -0.69% | Upgrade
|
| Gross Profit | 71.96 | 79.2 | 86.16 | 97.07 | 122.47 | 205.2 | Upgrade
|
| Selling, General & Admin | 57.96 | 52.89 | 45.48 | 32.54 | 27.36 | 26.25 | Upgrade
|
| Research & Development | 136.87 | 163.52 | 164.52 | 174.11 | 136.76 | 142.21 | Upgrade
|
| Operating Expenses | 194.83 | 216.41 | 210 | 206.65 | 164.11 | 168.46 | Upgrade
|
| Operating Income | -122.87 | -137.21 | -123.84 | -109.57 | -41.64 | 36.74 | Upgrade
|
| Interest Expense | -11.51 | -5.15 | - | - | - | - | Upgrade
|
| Interest & Investment Income | 16.26 | 11.36 | 1.57 | 2.02 | 6.47 | 8.82 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 0.08 | -0.03 | 0.15 | - | Upgrade
|
| Pretax Income | -118.12 | -131 | -122.19 | -107.58 | -35.02 | 45.56 | Upgrade
|
| Income Tax Expense | -2.79 | 2.82 | -0.43 | -28.58 | 1.15 | -0.83 | Upgrade
|
| Net Income | -115.33 | -133.82 | -121.76 | -79 | -36.17 | 46.38 | Upgrade
|
| Net Income to Common | -115.33 | -133.82 | -121.76 | -79 | -36.17 | 46.38 | Upgrade
|
| Net Income Growth | - | - | - | - | - | -35.54% | Upgrade
|
| Shares Outstanding (Basic) | 21 | 21 | 21 | 20 | 20 | 20 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 21 | 21 | 20 | 20 | 21 | Upgrade
|
| Shares Change (YoY) | 1.10% | 1.78% | 2.14% | 1.16% | -4.90% | 1.54% | Upgrade
|
| EPS (Basic) | -5.46 | -6.38 | -5.91 | -3.92 | -1.81 | 2.37 | Upgrade
|
| EPS (Diluted) | -5.46 | -6.38 | -5.91 | -3.92 | -1.81 | 2.21 | Upgrade
|
| EPS Growth | - | - | - | - | - | -36.49% | Upgrade
|
| Free Cash Flow | -100.33 | -112.21 | -86.91 | -70.75 | 5.64 | 66 | Upgrade
|
| Free Cash Flow Per Share | -4.75 | -5.35 | -4.22 | -3.51 | 0.28 | 3.15 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | -170.74% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | Upgrade
|
| Profit Margin | -160.27% | -168.95% | -141.31% | -81.38% | -29.53% | 22.60% | Upgrade
|
| Free Cash Flow Margin | -139.43% | -141.67% | -100.87% | -72.88% | 4.61% | 32.16% | Upgrade
|
| EBITDA | -120.34 | -134.84 | -120.87 | -106.24 | -38 | 40 | Upgrade
|
| EBITDA Margin | -167.23% | -170.24% | -140.29% | -109.44% | -31.02% | 19.49% | Upgrade
|
| D&A For EBITDA | 2.53 | 2.37 | 2.97 | 3.33 | 3.64 | 3.26 | Upgrade
|
| EBIT | -122.87 | -137.21 | -123.84 | -109.57 | -41.64 | 36.74 | Upgrade
|
| EBIT Margin | -170.74% | -173.23% | -143.74% | -112.88% | -34.00% | 17.90% | Upgrade
|
| Revenue as Reported | 71.96 | 79.2 | 86.16 | 97.07 | - | 205.2 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.